|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
Transfer of global rights for Eklira and Duaklir to Covis Pharma completed |
|||||||||||
|
|
|||||||||||
|
5 January 2022
AstraZeneca has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). |
|||||||||||
|